Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Large Growth in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 36,688 shares, an increase of 25.9% from the December 15th total of 29,141 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average trading volume of 94,355 shares, the short-interest ratio is presently 0.4 days. Based on an average trading volume of 94,355 shares, the short-interest ratio is presently 0.4 days. Approximately 0.7% of the shares of the stock are sold short.

Revelation Biosciences Price Performance

NASDAQ REVB traded up $0.05 during mid-day trading on Friday, hitting $0.95. The company’s stock had a trading volume of 76,649 shares, compared to its average volume of 89,457. Revelation Biosciences has a 52-week low of $0.76 and a 52-week high of $20.93. The stock’s fifty day simple moving average is $0.92 and its two-hundred day simple moving average is $1.68. The firm has a market capitalization of $5.62 million, a P/E ratio of -0.03 and a beta of -0.14.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.43). On average, equities analysts forecast that Revelation Biosciences will post -49.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Revelation Biosciences in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Revelation Biosciences stock. Armistice Capital LLC bought a new stake in Revelation Biosciences, Inc. (NASDAQ:REVB) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 80,000 shares of the company’s stock, valued at approximately $114,000. Armistice Capital LLC owned approximately 0.52% of Revelation Biosciences as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.